Promising Dividend Stocks To Follow Now - September 20th

Key Points

• Exxon Mobil, Chevron, Amgen, Direxion Daily TSLA Bull 2X Shares, and Merck & Co. are currently the top five dividend stocks recommended to watch, according to MarketBeat's stock screener.
• The companies listed are characterized by their steady cash flows and regular dividend payments, which make them appealing for investors seeking regular income.
• Exxon Mobil and Chevron are both heavily involved in the energy sector, while Amgen focuses on human therapeutics, highlighting diverse sector representation among the recommended stocks.

Exxon Mobil, Chevron, Amgen, Direxion Daily TSLA Bull 2X Shares, and Merck & Co., Inc. are the five Dividend stocks to watch today, according to MarketBeat's stock screener tool. Dividend stocks are shares of companies that regularly distribute a portion of their earnings to shareholders in the form of dividends. These companies tend to be more mature and generate steady cash flows, making their stock a potential source of regular income for investors. These companies had the highest dollar trading volume of any Dividend stocks within the last several days.

Exxon Mobil (XOM)

Exxon Mobil Corporation engages in the exploration and production of crude oil and natural gas in the United States and internationally. It operates through Upstream, Energy Products, Chemical Products, and Specialty Products segments. The Upstream segment explores for and produces crude oil and natural gas.

Read Our Latest Research Report on XOM

Chevron (CVX)

Chevron Corporation, through its subsidiaries, engages in the integrated energy and chemicals operations in the United States and internationally. The company operates in two segments, Upstream and Downstream. The Upstream segment is involved in the exploration, development, production, and transportation of crude oil and natural gas; processing, liquefaction, transportation, and regasification of liquefied natural gas; transportation of crude oil through pipelines; transportation, storage, and marketing of natural gas; and carbon capture and storage, as well as a gas-to-liquids plant.

Read Our Latest Research Report on CVX

Amgen (AMGN)

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Read Our Latest Research Report on AMGN

Direxion Daily TSLA Bull 2X Shares (TSLL)

Read Our Latest Research Report on TSLL

Merck & Co., Inc. (MRK)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Read Our Latest Research Report on MRK

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.